Evidence map›Paper›PMID 41259896›Full record

SynthesisESMO open2025

The risk of lung cancer from vaping or e-cigarette usage: a systematic review.

S Mohapatra, A Tiwari, A Kandala, R Winayak, A Ghose, R Das, M Hasanova, M Gunani, G Jaswal, S Mitra and 8 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Vaping-related lung disease: a narrative review.Journal of thoracic disease · 2026
    Review
  4. Toxicity and Appeal of Flavoured E-Cigarettes and Flavour Ban Outcomes: A Narrative Review.International journal of environmental research and public health · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

S MohapatraGeneral Internal Medicine Doctorate Programme, University of Hertfordshire, Hatfield, UK; The Misdiagnosis Association and Research Institute, Beverly Hills, USA.
A TiwariDepartment of Oncology, Princess Alexandra Hospital NHS Trust, Harlow, UK; Barts Cancer Institute, Cancer Research UK City of London Centre, Queen Mary University of London, London, UK; United Kingdom and Ireland Global Cancer Network, Manchester, UK.
A KandalaUniversity College London Medical School, London, UK.
R WinayakUnited Kingdom and Ireland Global Cancer Network, Manchester, UK; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Foundation Trust, Maidstone, UK.
A GhoseBarts Cancer Institute, Cancer Research UK City of London Centre, Queen Mary University of London, London, UK; United Kingdom and Ireland Global Cancer Network, Manchester, UK; Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; Department of Research and Innovation, Medway NHS Foundation Trust, Gillingham, UK; Prevention, Early Detection and Screening Network, European Cancer Organisation, Brussels, Belgium. Electronic address: aruni.ghose1@gmail.com.
R DasFaculty of Medicine and Health Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
M HasanovaDivision of Biosciences, University College London, London, UK.
M GunaniDepartment of Medicine, Allegheny Health Network, Pittsburgh, USA.
G JaswalOnco-Life Cancer Centre, Satara, India.
S MitraFortis Cancer Institute, Fortis Memorial Research Institute, Gurugram, India.
V NoronhaDepartment of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.
A JainApollo Cancer Centre, Indraprastha Apollo Hospital, New Delhi, India; Deanesly Centre for Cancer Services, New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
F MerlettiDepartment of Medical Sciences, University of Turin, Turin, Italy.
A PassaroDivision of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
A CortelliniOperative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK.
A AddeoOncology Service, Geneva University Hospital, Geneva, Switzerland.
G L BannaDepartment of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
S BoussiosDepartment of Research and Innovation, Medway NHS Foundation Trust, Gillingham, UK; Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece; Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; Kent and Medway Medical School, University of Kent, Canterbury, UK; Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, UK; Faculty of Life Sciences and Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; AELIA Organization, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActive tobacco smoking remains the primary etiological factor for lung cancer, the leading cause of cancer-related mortality worldwide. The use of electronic cigarettes (ECs) has recently emerged as a potential public health concern due to its suspected association with respiratory and oncogenic outcomes. This study aimed to evaluate the association between EC use and the incidence of lung cancer through a systematic review of existing scientific literature.

methodsA comprehensive literature search was conducted in PubMed, the Cochrane Library, Embase, ScienceDirect, Web of Science, Scopus, and Google Scholar up to June 2024. Original research articles of any study design that reported on the association between vaping or EC use and the risk of lung cancer were included. The quality of studies was assessed using the critical appraisal checklists for studies created by the Joanna Briggs Institute.

findingsOf 2252 identified citations, 5 articles were selected for qualitative analysis. These were primarily non-randomised observational designs published between 2019 and 2024. Sample sizes ranged from 3162 to 4 329 288 participants of both genders. A potential association between EC use and the risk of developing lung cancer was observed. Individuals who concurrently use conventional cigarettes and ECs exhibit an increased likelihood of lung cancer incidence.

conclusionThis systematic review suggests a potential association between EC use and an increased risk of lung cancer, particularly among dual users; however, causality cannot be established due to heterogeneity and limited longitudinal data.

Indexed as

Electronic Nicotine Delivery SystemsLung NeoplasmsVapingHumansIncidenceRisk Factorsconventional cigaretteselectronic cigaretteslung cancerlung functionvaping

Identifiers

PMID41259896
PMCPMC12670536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.